Incidence and survival for oropharynx and non-oropharynx head and neck cancers among veterans living with HIV.
Adult
CD4 Lymphocyte Count
Cohort Studies
Databases, Factual
HIV
/ isolation & purification
HIV Infections
/ epidemiology
Head and Neck Neoplasms
/ diagnosis
Humans
Male
Middle Aged
Oropharyngeal Neoplasms
/ diagnosis
Retrospective Studies
Risk Factors
SEER Program
Survival Rate
United States
/ epidemiology
Veterans
/ statistics & numerical data
HIV
head and neck cancer
incidence
survival
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
20
05
2020
revised:
27
08
2020
accepted:
28
09
2020
pubmed:
24
10
2020
medline:
5
8
2021
entrez:
23
10
2020
Statut:
ppublish
Résumé
People living with HIV/AIDS (PLWH) have an excess risk for head and neck squamous cell carcinoma (HNSCC) compared to the general U.S. population, but little is known about HIV-specific risk factors associated with the incidence and outcomes HNSCC. We aim to identify clinical and HIV-specific risk factors associated with oropharyngeal and non-oropharyngeal HNSCC incidence and outcomes separately. We constructed a retrospective cohort study of 45,052 PLWH aged 18 or above from the national Veteran Affairs (VA) Corporate Data from 1999 to 2015. We extracted demographic data and risk factor information, including history of alcohol abuse, smoking, CD4 count (cells/μl), and percent of follow-up time with undetectable HIV viral load as time-updated variables. We calculated the age-standardized incidence rates of oropharyngeal and non-oropharyngeal HNSCC and estimated adjusted hazard ratios (HR). We also examined overall survival using Kaplan-Meier curves and adjusted HR. The standardized incidence rate of oropharyngeal and non-oropharyngeal HNSCC in this veteran cohort of PLWH is 23.0 (95% confidence intervals (CIs): 17.1-28.9) and 55.4 (95% CI: 46.5-64.3) per 100,000 person-years, respectively. Nadir CD4 count ≤200 was associated with an increased risk of non-oropharyngeal HNSCC (HR: 1.78; 95% CI: 1.31-2.30 vs >200). Five-year overall survival of OPSCC (37.0%) was significantly lower than non-oropharyngeal HNSCC (49.1%). PLWH who receive care in the VA had higher age-adjusted HNSCC incidence rates than reported in the general population, suggesting that HIV and immunosuppression play a role. Additional studies should be conducted to study the interaction between HPV and HIV.
Sections du résumé
BACKGROUND
People living with HIV/AIDS (PLWH) have an excess risk for head and neck squamous cell carcinoma (HNSCC) compared to the general U.S. population, but little is known about HIV-specific risk factors associated with the incidence and outcomes HNSCC. We aim to identify clinical and HIV-specific risk factors associated with oropharyngeal and non-oropharyngeal HNSCC incidence and outcomes separately.
METHODS
We constructed a retrospective cohort study of 45,052 PLWH aged 18 or above from the national Veteran Affairs (VA) Corporate Data from 1999 to 2015. We extracted demographic data and risk factor information, including history of alcohol abuse, smoking, CD4 count (cells/μl), and percent of follow-up time with undetectable HIV viral load as time-updated variables. We calculated the age-standardized incidence rates of oropharyngeal and non-oropharyngeal HNSCC and estimated adjusted hazard ratios (HR). We also examined overall survival using Kaplan-Meier curves and adjusted HR.
RESULTS
The standardized incidence rate of oropharyngeal and non-oropharyngeal HNSCC in this veteran cohort of PLWH is 23.0 (95% confidence intervals (CIs): 17.1-28.9) and 55.4 (95% CI: 46.5-64.3) per 100,000 person-years, respectively. Nadir CD4 count ≤200 was associated with an increased risk of non-oropharyngeal HNSCC (HR: 1.78; 95% CI: 1.31-2.30 vs >200). Five-year overall survival of OPSCC (37.0%) was significantly lower than non-oropharyngeal HNSCC (49.1%).
CONCLUSIONS
PLWH who receive care in the VA had higher age-adjusted HNSCC incidence rates than reported in the general population, suggesting that HIV and immunosuppression play a role. Additional studies should be conducted to study the interaction between HPV and HIV.
Identifiants
pubmed: 33094910
doi: 10.1002/cam4.3539
pmc: PMC7774719
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
9326-9335Subventions
Organisme : CSRD VA
ID : I01 CX001430
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA206476
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA022453
Pays : United States
Informations de copyright
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Adv Ther. 2018 Mar;35(3):255-260
pubmed: 29511982
Sci Rep. 2020 Jan 14;10(1):243
pubmed: 31937831
Fed Pract. 2018 Aug;35(Suppl 5):S44-S47
pubmed: 30766403
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Laryngoscope. 2011 Jan;121(1):102-5
pubmed: 21046549
J Acquir Immune Defic Syndr. 2019 Jul 1;81(3):e65-e72
pubmed: 30939533
Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):122-33
pubmed: 22045700
PLoS One. 2013 Dec 18;8(12):e81355
pubmed: 24367482
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Lancet HIV. 2017 Nov;4(11):e495-e504
pubmed: 28803888
World J Otorhinolaryngol Head Neck Surg. 2018 Apr 11;4(4):278-281
pubmed: 30564792
Laryngoscope Investig Otolaryngol. 2019 Oct 17;4(6):617-623
pubmed: 31890879
Oral Oncol. 2010 Jul;46(7):492-6
pubmed: 20227331
Laryngoscope. 2016 May;126(5):1091-6
pubmed: 26451875
Ann Intern Med. 2008 May 20;148(10):728-36
pubmed: 18490686
Arch Intern Med. 2000 Nov 27;160(21):3252-7
pubmed: 11088086
J Natl Cancer Inst. 2005 Mar 16;97(6):425-32
pubmed: 15770006
J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):603-10
pubmed: 24326607
AIDS. 2006 Aug 1;20(12):1645-54
pubmed: 16868446
J Clin Oncol. 2015 Oct 10;33(29):3293-304
pubmed: 26351330
Surg Oncol Clin N Am. 2015 Jul;24(3):379-96
pubmed: 25979389
Am J Epidemiol. 2013 Sep 15;178(6):885-7
pubmed: 23900552
Strahlenther Onkol. 2015 Mar;191(3):209-16
pubmed: 25252603
Int J Cancer. 2007 Jul 1;121(1):143-50
pubmed: 17354235
Curr Opin HIV AIDS. 2017 Jan;12(1):31-38
pubmed: 27607596
PLoS Pathog. 2018 Apr 13;14(4):e1006973
pubmed: 29652923
J Oral Maxillofac Surg. 2017 Dec;75(12):2562-2572
pubmed: 28618252
Am J Gastroenterol. 2001 Jul;96(7):2013-8
pubmed: 11467626
Mil Med. 2017 Jul;182(7):e1883-e1891
pubmed: 28810986
Oral Oncol. 2014 Dec;50(12):1169-76
pubmed: 25301563
Clin Cancer Res. 2018 Jan 1;24(1):6-13
pubmed: 28751445
Curr HIV/AIDS Rep. 2012 Sep;9(3):223-30
pubmed: 22618079
J Otolaryngol Head Neck Surg. 2018 Sep 21;47(1):59
pubmed: 30241572
Popul Health Metr. 2006 Apr 10;4:2
pubmed: 16606453
HIV Med. 2019 Sep;20(8):567-570
pubmed: 31131549
Immunol Res. 2012 Dec;54(1-3):266-74
pubmed: 22454102